The release of the snapshot containing the respective simulations can be found here:
https://github.com/Open-Systems-Pharmacology/Carbamazepine-Efavirenz-DDI/releases/tag/vXX

The carbamazepine-efavirenz interaction was evaluated using one clinical DDI study ([Ji 2008](#4-references)).



| DataID | Enzyme | Perpetrator / victim      | Study design                                                 | Clinical study           |
| ------ | ------ | ------------------------- | ------------------------------------------------------------ | ------------------------ |
| 959    | CYP3A4 | Carbamazepine / efavirenz | Study Arm 1:<br />Carbamazepine (starting with the 15<sup>th</sup> dose of efavirenz): 200 mg po QD for 3 days, followed by 200 mg po BID for 3 days, followed by 400 mg po QD for 16 days<br />Efavirenz: 600 mg po QD for 35 days | [Ji 2008](#4-references) |
| 961    | CYP3A4 | Efavirenz / carbamazepine | Study Arm 2:<br />Efavirenz (starting with the 25<sup>th</sup> dose of carbamazepine): 600 mg po QD for 14 days<br />Carbamazepine: 200 mg po QD for 3 days, followed by 200 mg po BID for 3 days, followed by 400 mg po QD for 30 days | [Ji 2008](#4-references) |


